INVESTOR PRESENTATION
2022-02-25LL

ACTRIMS Investor Call

Sanofi was pleased to invite investors and analysts to participate in a live webcast discussing tolebrutinib data presented during the ACTRIMS scientific program (February 24-26,2022).

Featuring

  • Dietmar Berger
    Global Head of Development,
  • Tom Snow
    Global Franchise Head,
    Neurology
  • Erik Wallstroem
    Therapeutic Area Head,
    Multiple Sclerosis
  • Anthony Traboulsee
    Professor and Research
    Chair of the MS Society of
    Canada at the University of
    British Columbia,Vancouver
  • Tim Turner
    Global Project Head,
    Neurology